NCT04650204View on ClinicalTrials.gov

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Intractable EpilepsyMalignant GliomaSeizure DisorderWHO Grade 2 GliomaWHO Grade 3 Glioma
Interventions
DRUG

Anticonvulsant Agent

Given ASD

DRUG

Perampanel

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04650204 - Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy | Biotech Hunter | Biotech Hunter